J Korean Pediatr Soc.  1999 Apr;42(4):472-483.

Clinical Trial of Domestically Developed Bovine Lung Surfactant YY-38 in Neonatal Respiratory Distress Syndrome

• Lee C
• Kim JN
• Park MS
• Park MS
• Yoon SW
• Chang W
• Namgung R
• Park KI
• Han DG

Abstract

PURPOSE: We previously reported modified bovine lung surfactant YY-38(Newfactan ) had a low surface tension, good hysteresis, and exhibited good pressure-volume curve in animal experiment(J Korean Pediatr Asso 1997;40:771-85). We performed multicenter clinical trial of Newfactan in neonatal RDS.
METHODS
Seventy-seven infants with RDS(GA 31.8+/-2.9 wks and BW 1,809+/-592 gm) in 4 NICU were enrolled. After administration of Newfactan , we analyzed ventilator parameters and outcomes in 71 infants excluding mortality cases(n=6), and also compared risk factors between response(n=53) and redosing group(n=18).
RESULTS
Newfactan was administered at 6.8+/-7.2 hr after birth. Ventilator parameters such as FiO2, alveolar-arterial oxygen difference(a-A PO2) and oxygenation index(OI) except mean airway pressure(MAP) were significantly improved from six hours after administration. All parameters were improved at 24 hours after administration and persisted for 5 days. Outcomes were as follows; PDA(n=24), BPD(n=16), IVH(n=13), sepsis(n=9), ROP(n=7), pneumothorax(n=4) NEC(n=3), PIE(n=2), and pulmonary hemorrhage(n=1). All patients survived 30 days after birth. Redosing rate was 25%. The incidence of PDA was greater in redosing(56%) than in response group(26 %)(P=0.025).
CONCLUSION
In prospective multicenter clinical trial, Newfactan was effective in the treatmentof RDS.

Keyword

Clinical trial; Modified bovine lung surfactant; Newfactan; Respiratory distress syndrome

MeSH Terms

Animals
Humans
Incidence
Infant
Lung*
Mortality
Oxygen
Parturition
Prospective Studies
Respiratory Distress Syndrome, Newborn*
Risk Factors
Surface Tension
Ventilators, Mechanical
Oxygen